Tecan H1 2026 outlook highlights growth, rising costs

Swiss life sciences equipment maker Tecan on Monday unveiled its first-half 2026 outlook, forecasting revenue growth amid elevated transformation costs.

The company’s presentation slides, released to investors, emphasized continued expansion in core markets while detailing the financial impact of ongoing strategic initiatives. Tecan did not provide specific revenue or profit figures in the slides, but outlined key priorities including operational efficiency improvements and product innovation.

The transformation costs, linked to restructuring and technology investments, are expected to weigh on near-term profitability, the slides indicated. Analysts noted that while the initiatives may pressure margins, they aim to position Tecan for long-term growth in the life sciences sector.

Tecan’s outlook follows a period of robust demand for laboratory automation and diagnostic equipment, driven by biopharmaceutical research and healthcare applications. The company has not disclosed whether the cost pressures will extend beyond the first half of 2026.

Investor reactions to the slides were not immediately available. Tecan’s shares were trading flat in pre-market European trading on Monday, reflecting a cautious response to the outlook.